07:21 AM EST, 03/03/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported Monday a Q4 net loss of $0.29 per diluted share, narrower than its loss of $0.35 per share a year earlier.

Analysts polled by FactSet expected a loss of $0.25.

Revenue for the quarter ended Dec. 31 was $17.1 million, up from $14.8 million a year earlier.

Analysts surveyed by FactSet expected $17.2 million.

As of Dec. 31, the company said it had $392.1 million in cash and cash equivalents on hand, and expected it could fund operations into 2028.